This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, H. H. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Chen, H. H. Articles by Burnett, J. C., Jr Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB SODIUM Related Collections Cardio-renal physiology/pathophysiology Animal models of human disease Heart failure - basic studies Autonomic, reflex, and neurohumoral control of circulation

(Hypertension. 2001;38:187.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure

Horng H. Chen; John G. Lainchbury; Yuzuru Matsuda; Gail J. Harty; John C. Burnett, Jr

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn.

Correspondence to Horng H. Chen MB, BCh, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester MN 55905. E-mail chen.horng{at}mayo.edu

Abstract—— Mild heart failure is characterized by increases in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in the absence of activation of the renin-angiotensin-aldosterone system (RAAS). Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11, which degrades the natriuretic peptides (NPs) and ACE. In a well-characterized canine model of mild heart failure produced by ventricular pacing at 180 bpm for 10 days, we defined the renal and humoral actions of acute VP inhibition with omapatrilat (OMA, n=6) and acute ACE inhibition (n=5) alone with fosinoprilat. We also sought to determine whether the NPs participate in the renal actions of acute VP inhibition by the administration of OMA together with an intrarenal administration of the NP receptor antagonist HS-142-1 (n=5). OMA resulted in a greater natriuretic response than did ACE inhibition in association with increases in plasma cGMP, ANP, BNP, urinary cGMP, urinary ANP excretion, and glomerular filtration rate (P<0.05 for OMA versus ACE inhibition). Plasma renin activity was increased only in the group subjected to ACE inhibition. Administration of intrarenal HS-142-1 attenuated the renal properties of OMA in association with a decrease in urinary cGMP excretion despite similar increases in plasma ANP and BNP. This study provides new insight into a unique new pharmacological agent that has beneficial renal actions in experimental mild heart failure beyond the actions that are observed with ACE inhibition alone and that are linked to the NP system.

Key Words: natriuretic peptides • heart failure • renin • angiotensin

This article has been cited by other articles:

				F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF]

				Z. A. Abassi, A. Yahia, S. Zeid, T. Karram, E. Golomb, J. Winaver, and A. Hoffman Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H722 - H728. [Abstract] [Full Text] [PDF]

				S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]

				S.-J. Shi, E. Vellaichamy, S. Y. Chin, O. Smithies, L. G. Navar, and K. N. Pandey Natriuretic peptide receptor A mediates renal sodium excretory responses to blood volume expansion Am J Physiol Renal Physiol, October 1, 2003; 285(4): F694 - F702. [Abstract] [Full Text] [PDF]

				K. H Chee, K. Amudha, N. A Hussain, H. K Haizal, A.-M. J Choy, and C. C Lang Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 140 - 148. [Abstract] [PDF]

				H. H. Chen, M. M. Redfield, L. J. Nordstrom, A. Cataliotti, and J. C. Burnett Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure Am J Physiol Renal Physiol, May 1, 2003; 284(5): F1115 - F1119. [Abstract] [Full Text] [PDF]

				D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]

				O. V. Fedorova, M. I. Talan, N. I. Agalakova, M.-T. Droy-Lefaix, E. G. Lakatta, and A. Y. Bagrov Myocardial PKC {beta}2 and the Sensitivity of Na/K-ATPase to Marinobufagenin Are Reduced by Cicletanine in Dahl Hypertension Hypertension, March 1, 2003; 41(3): 505 - 511. [Abstract] [Full Text] [PDF]

				M. Azizi, M. Lamarre-Cliche, A. Labatide-Alanore, A. Bissery, T. T. Guyene, and J. Menard Physiologic Consequences of Vasopeptidase Inhibition in Humans: Effect of Sodium Intake J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2454 - 2463. [Abstract] [Full Text] [PDF]

				C. V. Maniu, D. M. Meyer, and M. M. Redfield Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension Hypertension, October 1, 2002; 40(4): 528 - 534. [Abstract] [Full Text] [PDF]

				H. H. Chen, J. G. Lainchbury, and J. C. Burnett Jr Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1186 - 1191. [Abstract] [Full Text] [PDF]

				A. Dawson and A. D Struthers Review: Vasopeptidase inhibitors in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 156 - 159. [Abstract] [PDF]

				F. Regamey, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men Hypertension, September 1, 2002; 40(3): 266 - 272. [Abstract] [Full Text] [PDF]

				F. Piquard, R. Richard, A. Charloux, S. Doutreleau, T. Hannedouche, G. Brandenberger, and B. Geny Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients J Appl Physiol, August 1, 2002; 93(2): 569 - 575. [Abstract] [Full Text] [PDF]

				A. Cataliotti, G. Boerrigter, H. H. Chen, M. Jougasaki, L. C. Costello, T. Tsuruda, S.-C. Lee, L. S. Malatino, and J. C. Burnett Jr Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure Circulation, February 5, 2002; 105(5): 639 - 644. [Abstract] [Full Text] [PDF]

				R. Corti, J. C. Burnett Jr, J. L. Rouleau, F. Ruschitzka, and T. F. Luscher Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? Circulation, October 9, 2001; 104(15): 1856 - 1862. [Abstract] [Full Text] [PDF]

				H. H. Chen, J. G. Lainchbury, G. J. Harty, and J. C. Burnett Jr Maximizing the Natriuretic Peptide System in Experimental Heart Failure: Subcutaneous Brain Natriuretic Peptide and Acute Vasopeptidase Inhibition Circulation, February 26, 2002; 105(8): 999 - 1003. [Abstract] [Full Text] [PDF]